Not just an ophthalmology-focused CRO, Iris Pharma helps clients around the world navigate every stage of the drug and device development process and delivers customized solutions for: • Assessing possible therapeutic effect in ocular diseases • Adding value to promising drug candidates or medical devices • Designing development plans and preclinical packages and carrying out studies to proceed with confidence from bench to bedside • Providing the comprehensive clinical development services you need, from First-in-Human through Phase IV and Post-marketing follow-through We accompany start-up companies, biotechnology companies, large pharmaceutical companies, pharmaceutical labs, universities, research organizations and consultants in their ophthalmology projects. Our assets: • 32 years of experience in the field of ophthalmology research • All ophthalmic indications mastered • 70+ FDA, PMDA & EMA new ocular drug approvals and ophthalmic medical device marketing authorizations • State-of-the-art medical and scientific equipment • Highly specialized and qualified staff • Statement of compliance with GLP and GCLP • Adherence to all trial-related requirements (ICH-GCP) • French research tax credit accreditation (CIR)
Looking for a particular IRIS PHARMA employee's phone or email?
The IRIS PHARMA annual revenue was $10 million in 2026.
Yann Quentric is the CEO at Iris Pharma of IRIS PHARMA.
49 people are employed at IRIS PHARMA.
IRIS PHARMA is based in La Gaude, Wallis and Futuna.
The NAICS codes for IRIS PHARMA are [325, 3254, 32541, 32].
The SIC codes for IRIS PHARMA are [28, 283].